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It is not clear to what extent associations between schizophrenia, cannabis use and cigarette use are due 
to a shared genetic etiology. We therefore examined whether schizophrenia genetic risk associates with 
longitudinal patterns of cigarette and cannabis use in adolescence, and mediating pathways for any 
association to inform potential reduction strategies.  
Methods 
Associations between schizophrenia polygenic scores and longitudinal latent classes of cigarette and 
cannabis use from ages 14 years to 19 years were investigated in up to 3925 individuals in the Avon 
Longitudinal Study of Parents and Children. Mediation models were estimated to assess the potential 
mediating effects of a range of cognitive, emotional, and behavioral phenotypes. 
Results 
The schizophrenia polygenic score, based on single nucleotide polymorphisms meeting a training-set p-
threshold of 0.05, was associated with late-onset cannabis use (OR=1.23; 95% CI=1.08,1.41), but not with 
cigarette or early-onset cannabis classes. This association was not mediated through lower IQ, 
victimization, emotional difficulties, antisocial behavior, impulsivity, or poorer social relationships during 
childhood. Sensitivity analyses adjusting for genetic liability to cannabis or cigarette use, using polygenic 
scores excluding the CHRNA5-A3-B4 gene cluster, or basing scores on a 0.5 training-set p-threshold, 
provided results consistent with our main analyses.  
Conclusions 
Our study provides evidence that genetic risk for schizophrenia is associated with patterns of cannabis 
use during adolescence. Investigation of pathways other than the cognitive, emotional, and behavioural 
phenotypes examined here is required to identify modifiable targets to reduce the public health burden 
of cannabis use in the population. 
 
 







Schizophrenia is a highly heritable, severe psychiatric disease with typical symptoms including positive 
symptoms such as hallucinations, delusions and thought disorder, negative symptoms such as apathy 
and avolition, and cognitive dysfunction. Genome-wide association studies (GWAS) provide strong 
evidence of multiple independent loci contributing to the etiology of schizophrenia (Pardiñas et al., 
2018; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). However, whilst 
individual loci have small effects on risk, multi-locus approaches show that cumulatively, even 
moderately associated alleles explain at least a third of schizophrenia genetic risk (Purcell et al., 2009; 
Ripke et al., 2013). Based on these alleles, an individual’s genetic liability can be quantified using a 
polygenic score, a valuable tool when investigating shared genetics between disorders and how genetic 
risk is manifest throughout the life course (Hubbard et al., 2016; Jones et al., 2016).  
Cannabis use is more common in individuals with schizophrenia than in the general population (Green, 
Young, & Kavanagh, 2005), and a large body of evidence from observational (Moore et al., 2007) and 
experimental (D'Souza et al., 2004) studies support a causal effect of cannabis use on psychosis. 
However, some recent studies (Carey et al., 2016; Power et al., 2014; Reginsson et al., 2017; Verweij et 
al., 2017), though not all (Guloksuz et al., 2019), have found that genetic liability to schizophrenia (as 
captured by polygenic scores) is associated with cannabis use, suggesting that the association between 
cannabis and schizophrenia might be partly genetically confounded, or represent a pathway from 
schizophrenia risk to cannabis use. The latter may result from early manifestations of schizophrenia 
liability that may increase an individual’s likelihood to start using cannabis, for example, experiencing 
difficulties with peers (Cannon et al., 2001; Malmberg, Lewis, David, & Allebeck, 1998). If a bi-directional 
relationship does exist, then identifying the mechanisms by which schizophrenia genetic risk increases 
risk of cannabis use could provide important insights about targets to prevent cannabis use in the 
population, and particularly in those at genetically high risk for schizophrenia where cannabis reduction 




Schizophrenia is also associated with a higher prevalence of tobacco smoking behaviors compared with 
the general population (de Leon & Diaz, 2005; Dickerson et al., 2013). As such, the possibility that 
cigarette smoking might increase risk for schizophrenia has gained attention (Gurillo, Jauhar, Murray, & 
MacCabe, 2015), although recent work shows that evidence consistent with causal effects on psychotic 
experiences are much stronger for cannabis use than they are for tobacco use (Jones et al., 2018). 
Schizophrenia polygenic risk, and a schizophrenia GWAS hit in the CHRNA5-A3-B4 gene cluster, are 
associated with cigarette smoking phenotypes, including initiation, dependence and heaviness 
(Reginsson et al., 2017; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014) 
which, similar to the findings for cannabis use, raises questions regarding a shared genetic etiology and 
direction of effect between cigarette use and schizophrenia, and the potential to gain insights into 
mechanisms leading to cigarette use in the population.  
We identified, a priori to any analyses, a number of potentially modifiable pathways through which 
genetic risk for schizophrenia could theoretically lead to adolescent substance use. Based on evidence of 
association with both genetic/familial risk for schizophrenia, and with substance use, these included 
peer-victimization, poorer social relationships, deficits in cognitive ability and impulsivity, and emotional 
or behavioral problems during childhood (Courtney, Mejia, & Jacobus, 2017; Varese et al., 2012; 
Welham, Isohanni, Jones, & McGrath, 2009).  
Whilst understanding whether genetic risk for schizophrenia is associated with specific patterns of 
substance use, and the pathways involved in these relationships, could provide important insights into 
the etiology of both schizophrenia and substance use disorders, disentangling such associations may be 
hindered by measurement error in the outcomes, the high correlation between cigarette and cannabis 
use that makes it difficult to study independent effects of these substances, and by experimental and 
fluctuating use over time which are difficult to capture with single time-point assessments. To overcome 
some of these difficulties, we previously used longitudinal latent class analysis (LLCA) of repeated 
measurements of adolescent cigarette and cannabis use to identify subgroups of individuals based on 




brief experimentation with these substances (Jones et al., 2018). The current study therefore aims to 
use these latent classes to: i) examine whether schizophrenia genetic risk is associated with patterns of 
cigarette and cannabis use in adolescence, and ii) examine whether genetic effects on substance use are 




The sample consisted of participants from the Avon Longitudinal Study of Parents and Children (ALSPAC) 
(see Supplementary Methods) (Boyd et al., 2013; Fraser et al., 2013). Details of available data are 
accessible through a searchable data dictionary and variable search tool 
(http://www.bristol.ac.uk/alspac/researchers/data-access/data-dictionary). Ethical approval for the 
study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics 
Committees (http://www.bristol.ac.uk/alspac/researchers/research-ethics/). Consent for biological 
samples has been collected in accordance with the Human Tissue Act (2004). Informed consent for the 
use of data collected via questionnaires and clinics was obtained from participants following the 
recommendations of the ALSPAC Ethics and Law Committee at the time. 
Genetic data 
Genetic data were acquired using the Illumina HumanHap550 quad genome-wide single nucleotide 
polymorphism (SNP) genotyping platform from 9912 participants. Following quality control assessment 
and imputation (see Supplementary Methods), genetic data was available for 7977 ALSPAC individuals. 
Measures 
Polygenic scores 
Polygenic scores for schizophrenia were constructed for each ALSPAC individual using data from the 




training set. Following quality control (see Supplementary Methods), polygenic scores were calculated 
using the PLINK (v1.9) (Chang et al., 2015; Purcell et al., 2007) ‘score’ command following the 
methodology described previously (Purcell et al., 2009).   
For the primary analysis, scores were constructed using a list of SNPs with a GWAS training set p-value 
threshold ≤ 0.05,which optimally captures phenotypic variance in schizophrenia (Schizophrenia Working 
Group of the Psychiatric Genomics Consortium, 2014). Scores were weighted by the logarithm of the 
odds ratio (OR) for schizophrenia reported by the training set. 
For sensitivity analyses, additional polygenic scores were created based on different GWAS training set 
p-value thresholds (P ≤ 0.5, 1e-5 and 5e-8 [genome-wide significant]) and after excluding the CHRNA5-A3-
B4 nicotinic receptor gene cluster (chromosome 15: 78- 79.5Mb), a loci which is strongly associated with 
smoking cigarette quantity and nicotine dependence (Saccone et al., 2009; Tobacco Genetics 
Consortium, 2010) and also genome-wide significantly associated with schizophrenia (Pardiñas et al., 
2018; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). Weighted polygenic 
scores were also constructed for cigarette smoking initiation and cannabis use initiation using results 
from the GWAS and Sequencing Consortium of Alcohol and Nicotine use (GSCAN) tobacco and alcohol 
use GWAS (n = 1 232 091) (Liu et al., 2019) and from a cannabis use GWAS meta-analysis using data 
from the International Cannabis Consortium (ICC) and UK Biobank (n = 184 765) (Pasman et al., 2018), 
respectively, using SNPs meeting a p-value threshold ≤ 0.5 in the training set GWAS. As ALSPAC was a 
part of the GSCAN and ICC GWAS samples (Liu et al., 2019; Stringer et al., 2016), the SNPs and log ORs 
used to generate and weight the polygenic scores were from results after removal of ALSPAC and, due 
to data permissions, 23andMe from the GWAS meta-analyses. 
Repeated measures of cigarette and/or cannabis use 
Repeated measures of cigarette and/or cannabis use in ALSPAC were collected from clinic visits and 
questionnaires between approximate ages 14 and 19 years. At each time point, individuals were asked 
questions relating to their current use and frequency of use (see Supplementary Methods for more 




variable: “Non-users”, “Cigarette-only users” and “Cannabis users (either with or without cigarettes)” as 
previously described (Jones et al., 2018). 
Potential mediators 
Potential mediators were selected on the basis that they are all premorbid antecedents of 
schizophrenia, associated with familial risk of schizophrenia, and/or associated with substance use. 
These included: IQ (assessed via the Wechsler Intelligence Scale for Children (Wechsler, Golombok, & 
Rust, 1992) at age 8 years), victimization (from the Bullying and Friendship Interview Schedule (Wolke, 
Woods, Bloomfield, & Karstadt, 2000) at age 8 years), emotional problems (Strengths and Difficulties 
Questionnaire [SDQ] (Goodman, 1999) sub-scale score at age 9 years), antisocial behavior (assessed via 
a short structured interview at age 10 years), impulsivity (number of incorrect items on the stop signal 
task (150ms delay) (Handley, Capon, Beveridge, Dennis, & Evans, 2004) at age 10 years), friendship 
quality (based on 5 items from the Cambridge Friendship Questionnaire (Baron-Cohen & Wheelwright, 
2003) at age 12 years), and psychotic experiences (Psychosis-Like Symptom Interview [PLIKSi] (Horwood 
et al., 2008) at age 12 years). For more information, see Supplementary Methods. 
Statistical analysis 
Longitudinal latent class analysis 
Using the repeated, 3-category nominal variable of cigarette and cannabis use described above, LLCA 
was used to derive distinct behavior patterns of cigarette and/or cannabis use as previously described 
(Howe et al., 2017; Jones et al., 2018; Taylor et al., 2017) (see Supplementary Methods). Briefly, 
Individuals were included in the analysis if they had cigarette and cannabis use data present for 3 or 
more time points. Starting with one class, additional classes were added, and each time the model fit 
assessed using proportion of individuals in each class, sample size adjusted Bayesian Information 
Criterion (SSABIC) and Lo-Mendell-Rubin likelihood ratio test (LMR-LRT). The optimal number of classes 
that explained the variation within the data was achieved. LLCA was performed using MPlus version 8 




Our previous study using the same data found that a 5-class solution adequately describes the combined 
cigarette and cannabis use data between ages 14 to 19 years (Jones et al., 2018). The classes were 
defined as: non-users, early-onset cigarette-only users, early-onset cannabis users (with or without 
cigarette use), late-onset cigarette-only users and late-onset cannabis users (with or without cigarette 
use)(Jones et al., 2018). Based on the patterns of class membership across time (see Jones et al., 2018), 
early-onset and late-onset substance use are approximately defined as higher probability of use 
between approximate ages 14-16 years and higher probability of use between approximate ages 16-19 
years, respectively (see Supplementary Figure 1).  
Association analyses 
Multinomial logistic regression was used to assess whether polygenic scores predicted latent class 
membership. Associations were assessed using a manual implementation of the bias-adjusted three-
step method in MPlus (see Supplementary Methods and Heron et al. (2015) for more detail). Association 
analyses were conducted using individuals who had cigarette and cannabis use data present for 3 or 
more time points and genetic data.  
To investigate whether associations between schizophrenia polygenic scores and latent class 
membership were influenced by genetic overlap between variants associated with both schizophrenia 
and cannabis or cigarette use, analyses were also adjusted for the cigarette smoking initiation and 
cannabis use initiation polygenic scores. 
As it was not possible to incorporate information on frequency of substance use in our 5-class latent 
class approach as this resulted in an unstable model (Jones et al., 2018), we examined whether 
schizophrenia polygenic scores were associated with frequency of cannabis or cigarette use using data 
from single time-points. To aid future meta-analyses, the association between schizophrenia polygenic 
scores and cannabis and cigarette ever versus never use were also investigated. The association 
between schizophrenia polygenic scores and ever/never use and frequency of use were assessed using 






Mediation models were used to assess the direct effects of polygenic risk for schizophrenia on latent 
class membership and indirectly through each potential mediator. Mediation models were run in MPlus 
using a maximum likelihood estimator, and standard errors for indirect effects were calculated using a 
non-parametric bootstrapping approach with 100 replications. As two of the mediators were 
dichotomous measures, a counterfactual approach was implemented to allow for incorporation of the 
dichotomous mediators with effect estimates that are easily interpretable (Valeri & VanderWeele, 
2013). However, it is noted that for the models incorporating continuous mediators, this approach 
simplifies to product of coefficient strategy as we did not allow for an interaction between exposure and 
mediator.  
Class reparameterization  
As the main analyses were performed using multinomial logistic regression, the effect estimates are 
interpreted as the strength of association between the exposure and each outcome class in relation to a 
reference class, rather than the effect of the exposure on class membership in the whole population. To 
address whether this influenced our results, we repeated all analyses after reparametrizing the 
longitudinal latent classes (maintaining uncertainty in class membership) to examine, primarily, the 
effects for late-onset cannabis use as compared to all other classes combined in a logistic regression. 
Effects from these analyses therefore represent odds for membership in late-onset cannabis use class 
compared to membership in any other latent class.  
 
Results 
There was strong evidence that genetic risk for schizophrenia differed across the combined cigarette use 
and cannabis use latent classes (omnibus p = 0.004; Table 1). The schizophrenia polygenic score based 
on SNPs meeting a training sample p-threshold of 0.05 was associated with late-onset cannabis use as 




decreased odds of late-onset cigarette-only use (OR = 0.87; 95% CI = 0.76, 1.00) as compared to non-
use, but little evidence of association with increased odds of early-onset cigarette-only use (OR = 1.13; 
95% CI = 0.94, 1.36) or early-onset cannabis use (OR = 1.08; 95% CI = 0.87, 1.33). These associations 
persisted after adjusting for cigarette smoking initiation and cannabis use initiation polygenic scores 
(Table 1) which both showed evidence of association with the cigarette use and cannabis use latent 
classes (omnibus p < 0.001; Supplementary Table 1).  
Results were similar when excluding the CHRNA5-A3-B4 gene cluster, and when using a more relaxed p-
value threshold for inclusion of SNPs into the schizophrenia polygenic score (p-value threshold ≤ 0.5). 
However, evidence was weaker when using polygenic scores based on more stringent p-value 
thresholds (p ≤ 1e-5 or p ≤ 5e-8) for SNP inclusion, that capture very little variance in liability to 
schizophrenia (Supplementary Tables 2 and 3). 
Results were also similar following reparameterization of classes with evidence of an increased genetic 
liability for schizophrenia (p-value threshold ≤ 0.05) being associated with a 1.2-fold increase in odds 
(95% CI = 1.05, 1.37) of late-onset cannabis use as compared to all other classes combined 
(Supplementary Table 4). 
Evidence of association between the schizophrenia polygenic score and ever/never substance use as 
well as frequency of substance use was generally stronger for cannabis use than for cigarette use, and 
also stronger for measures of frequency of use in late adolescence and early adulthood than for 
measures of use in early adolescence (Supplementary Tables 5 and 6). 
There was weak evidence that genetic risk for schizophrenia was associated with lower quality of 
friendships (higher score indicates a lower friendship quality) (Beta = 0.06; 95% CI = -0.01, 0.13), and 
lower IQ score in childhood (Beta = -0.05; 95% CI = -0.07, -0.02), but less so with  emotional symptoms, 
victimization, antisocial behavior or impulsivity (Supplementary Figures 2 and 3). There was evidence 
that higher IQ and engagement in antisocial behavior were associated with an increased odds of late-




2.56). There was weaker evidence that a higher emotional symptoms score was associated with a 
reduction in late-onset cannabis use (OR = 0.91; 95% CI = 0.82, 1.01) (Supplementary Figure 2).  
In the mediation analysis, there was weak evidence that the effect of schizophrenia polygenic score on 
IQ score at age 8 years acts to reduce the effect of schizophrenia genetic risk on late-onset cannabis use 
(indirect effect through IQ at age 8 years: OR = 0.99; 95% CI = 0.97, 1.00), but little evidence that any 
other mediators affected this pathway (Table 2). Results were also similar following reparameterization 
of classes (Supplementary Table 7). 
 
Discussion 
We examined whether genetic risk for schizophrenia was associated with cigarette and cannabis use 
during adolescence within a general population cohort and, where appropriate, tested for mediating 
effects of a range of factors measured prior to our outcome measures. Our primary outcome measures 
were latent classes summarizing the use of cigarettes and cannabis between ages 14 and 19 years. As 
previously reported (Jones et al., 2018), our data was best summarized by 5 classes comprising 
individuals with early-onset cigarette-only use, late-onset cigarette-only use, early-onset cannabis use, 
late-onset cannabis use, and no use of either substance. In our primary analysis, using a training sample 
p-threshold of 0.05 that optimally captures variance in schizophrenia liability, we found that 
schizophrenia polygenic risk was most strongly associated with late-onset cannabis use. Early-onset 
cigarette and cannabis use class estimates were compatible with the late-onset cannabis use estimate. 
However, these estimates were less precise as the classes were substantially smaller and therefore 
analyses had lower power. Interestingly, we found that schizophrenia polygenic risk was also associated 
with a decreased odds of late-onset cigarette only use, however, this weak association did not survive 
after class reparameterization. 
Our findings are consistent with other studies showing that schizophrenia polygenic risk is associated 




Furthermore, results from both our primary results and sensitivity analyses provide evidence that 
genetic risk of schizophrenia is more strongly associated with cannabis use than with cigarette use.  
One interpretation of our findings is that genetic risk for schizophrenia confers a risk of substance use 
that is more specific for some drug classes than others, perhaps due to pleiotropic effects on more 
substance-specific biological pathways than ones that are common across addictive behaviors. However, 
as almost all individuals within the cannabis use class also use tobacco this class could just index a more 
severe phenotype. Therefore, genetic risk for schizophrenia could confer a risk of multiple substance 
use, for example through dopaminergic or opioid function that are biological pathways strongly 
implicated across all addictive behaviours (Koob & Volkow, 2016). 
It is also possible that the association with late-onset cannabis use is not due to pleiotropic effects of 
addiction-related biological pathways, but due to behavioral manifestations of schizophrenia genetic risk 
leading to adolescent use of cannabis. To explore this possibility we examined if the strongest 
association we observed in our primary analysis, between schizophrenia genetic risk and late-onset 
cannabis use, was mediated by lower childhood IQ, emotional problems, victimization, engagement in 
antisocial behavior, impulsivity or poorer social relationships, all of which are characteristics associated 
with increased risk of schizophrenia incidence or cannabis use (Courtney et al., 2017; Varese et al., 2012; 
Welham et al., 2009). Our results suggested that little to none of this association was mediated through 
these pathways, and indeed that ‘direct’ effects of schizophrenia genetic risk on late-onset cannabis use 
may be stronger than first observed. However, this does not exclude the possibility that other variables 
that we did not test mediate this relationship. 
Whilst the cognitive, emotional, and behavioral characteristics we examined did not mediate the 
relationship between schizophrenia genetic risk and cannabis use, identifying mediating phenotypes 
expressed in childhood or adolescence is important not just for understanding the mechanisms 
underlying addictive behavior, but also to inform potential targets for early intervention to prevent 
substance use and harmful consequences of this. The mediators we examined were measured in 




However, a potential limitation of this is that our results might not adequately reflect the relationship of 
schizophrenia genetic risk with those same characteristics in adolescence, when they might have a more 
immediate effect on substance use behavior.  
The association we observe here between schizophrenia genetic risk and cannabis use suggests either 
that the association between cannabis use and psychosis observed consistently in epidemiological 
studies (Gage, Hickman, & Zammit, 2016; Moore et al., 2007) is, at least in part, due to pleiotropy, or 
that cannabis has a causal effect on schizophrenia (and therefore risk variants for cannabis use will also 
be identified as risk variants for schizophrenia (Gage, Davey Smith, Ware, Flint, & Munafò, 2016) in 
adequately-powered GWASs where there would be many more cannabis users among cases than 
controls). In fact, despite the finding from this and other studies that schizophrenia genetic risk is 
associated with cannabis use, there is little evidence that shared genetic effects confound associations 
between cannabis use and risk of psychotic outcomes in epidemiological studies. For example, in a 
recent study we found strong evidence that classes of cannabis use were associated with subsequent 
risk of psychotic experiences, and that this was not attenuated after adjusting for family history of 
schizophrenia (Jones et al., 2018) or schizophrenia genetic risk score (Supplementary Table 8).  
One approach that has been used to examine causal effects of cannabis use on schizophrenia and assess 
the presence of genetic confounding (horizontal pleiotropy) is Mendelian randomization (MR). Evidence 
consistent with a causal effect of schizophrenia risk on likelihood of cannabis initiation, as well as weak 
evidence of a causal effect from cannabis initiation to schizophrenia has been reported (Gage, Jones, et 
al., 2016; Pasman et al., 2018). Similarly analyses have reported a bidirectional relationship between a 
measure of lifetime cigarette smoking (capturing smoking duration, heaviness and cessation) (Wootton 
et al., 2018) and schizophrenia risk. However, when there is little understanding of the biological effects 
of the genetic instruments used in MR analyses, bidirectional relationships such as these can be difficult 
to interpret (Davey Smith & Hemani, 2014), and therefore neither MR studies to date, nor our results 
here, lead to substantially stronger conclusions about the causal effects of cannabis and cigarettes on 




Whilst our findings cannot address whether cannabis use has a causal effect on schizophrenia, our 
results show that schizophrenia genetic liability does not lead to increased cannabis use through the 
mechanisms examined here, and that the investigation of other pathways is required to identify 
potentially modifiable targets to reduce the public health burden of cannabis use in the population.  
Strengths and limitations 
One of the strengths of our study is that we use a large, population-based cohort, with multiple 
measures of cigarette and cannabis use data over the whole adolescent period, and thus our results are 
much less prone to measurement error than if we had used single time-point measures of substance 
use, although it likely still exists to some extent. Furthermore, using a latent class approach with 
longitudinal data allows us to maximize use of data for individuals even where participation and 
question response has been sporadic, and hence minimize potential selection bias, despite the 
considerable levels of attrition over time. We also used the largest, most recent published GWASs of 
schizophrenia, cigarette use and cannabis use as training sets for derivation of our polygenic scores. 
Nevertheless, there are a number of limitations with our study.  
Whilst our use of latent classes derived from information on the combined use of cigarettes and 
cannabis use is useful for teasing out independent effects of schizophrenia genetic risk on these 
outcomes, it was not possible to define a class of individuals who use cannabis without tobacco, as most 
cannabis users smoke cannabis in combination with tobacco (Amos, Wiltshire, Bostock, Haw, & McNeill, 
2004), even when they self-report as being cigarette non-smokers (Gage et al., 2014). Furthermore, we 
have previously found that a substantial proportion of the people who smoke cigarettes most heavily 
also use cannabis (Gage et al., 2014), and thus the cigarette-only class might not include those who have 
been most heavily exposed to tobacco. Therefore, we cannot rule out whether the associations 
observed between schizophrenia genetic risk and the late-onset cannabis use class is driven by heavier 
cigarette use in these individuals than in those within the early-onset cigarette only or late-onset 




Another limitation is that it was not possible to incorporate information on frequency of substance use 
per time point within the combined cannabis and cigarette use model due to model instability. We 
therefore also examined frequency of cigarette use and cannabis use using single time-point measures 
and found no consistent evidence of association with genetic liability of schizophrenia, with the 
exception of increase odds of cannabis use frequency at ages 17 to 19 years. 
Furthermore, although we attempted to minimize genetic confounding by adjusting for cigarette and 
cannabis initiation polygenic scores, heterogeneity between training set GWAS samples (i.e. differing 
ages of participants) and substance use measures (i.e. measures combined experimental and regular 
users into a single group) may have reduced their power to detect genetic associations. Furthermore, 
polygenic scores for cigarette and cannabis use initiation explain only a small proportion of the variance 
for these phenotypes in independent samples. Hence, adjusting for cigarette and cannabis initiation 
polygenic scores may have not adequately removed confounding effects resulting from pleiotropy. It is 
also possible that our mediation effects are underestimated due to residual confounding. 
Finally, as our cohort only included data up to 19 years of age, it was not possible to examine effects of 
schizophrenia genetic risk on longer-term patterns, or long-term cumulative use of cannabis or 
cigarettes. Addressing these model limitations may become more tractable in the future. 
Conclusion 
In conclusion, our study provides evidence that genetic risk for schizophrenia is associated with patterns 
of cannabis use during adolescence, and that this is not mediated through other measured phenotypic 
manifestations of genetic risk for schizophrenia during childhood, including lower IQ, victimization, 
increased emotional difficulties, antisocial behavior, impulsivity, or poorer social relationships. Evidence 
of association between genetic risk for schizophrenia and cigarette use was weaker. Further studies 
need to examine longer-term patterns of use of these substances over time to minimize measurement 
error in allocation of substance use classes, and to establish the mechanisms by which these 
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Table 1. Associations between polygenic score for schizophrenia and subsequent cigarette and/or 
cannabis use as compared to non-use (N = 3925) 
P-value threshold for 
inclusion of SNPs into 


















OR (95% CI) 2 OR (95% CI) 2 OR (95% CI) 2 OR (95% CI) 2 P 
Unadjusted 








 (1.08, 1.41) 
0.004 
Adjusted 3 










Note: SNPs, single nucleotide polymorphisms; OR, odds ratio; 95% CI, 95% confidence interval; P, omnibus P-value 
for association between polygenic score and cigarette/cannabis use classes 
1 Class proportions for latent class membership based on the estimated model 
2 Compared to non-use class (class proportion for latent class membership based on the estimated model: 65.3%). 





Table 2. Total effect, direct effect and indirect effect of schizophrenia polygenic score (PT = 0.05) on late-
onset cannabis with/without cigarette use as compared to non-use through a range of potential 
mediators 
Mediator N 
Total Effect Direct Effect 
Indirect Effect via 
mediator 
OR (95% CI) OR (95% CI) OR (95% CI) 
Standardized measure of IQ  
at age 8 years 
3468 1.23 (1.06,1.44) 1.25 (1.07,1.46) 0.99 (0.97,1.00) 
Victimization 
 at age 8 years 
3371 1.22 (1.07,1.38) 1.22 (1.07,1.38) 1.00 (1.00,1.01) 
Emotional symptoms  
at age 9 years 
3522 1.20 (1.04,1.39) 1.20 (1.04,1.39) 1.00 (0.99,1.00) 
Antisocial behavior 
at age 10 years 
3533 1.26 (1.09,1.46) 1.26 (1.09,1.46) 1.00 (1.00,1.01) 
Impulsivity  
at age 10 years 
3344 1.22 (1.06,1.41) 1.22 (1.06,1.41) 1.00 (1.00,1.00) 
Friendship quality  
at age 12 years 
3542 1.27 (1.09,1.48) 1.27 (1.09,1.48) 1.00 (0.99,1.00) 
Psychotic experiences 
at age 12 years 
3572 1.26 (1.12,1.42) 1.26 (1.12,1.42) 1.00 (1.00,1.00) 
Note: OR, odds ratio; 95% CI, 95% confidence interval; PT, p-value threshold for inclusion of SNPs into polygenic 
score. Within the mediation models, higher emotional, impulsivity and friendship quality scores indicate more 
emotional problems, a higher level of impulsivity and worse friendship quality, respectively. 
 
 
